Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 3Unknown 2Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1

Conditions

Melanoma 2

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × oblimersen × Dermatologic × Clear all
NCT00070343 2014-01-06

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

National Cancer Institute (NCI)

Phase NA Unknown
Dermatologic

Melanoma

NCT00409383 2011-11-07

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Genta Incorporated

Phase 1 Unknown
28 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡